Methylprednisolone injection in treatment of birch pollen induced allergic rhinitis

Region Skåne0 个研究点目标入组 60 人开始时间: 2018年12月17日最近更新: 2024年2月19日

试验速览

暂无简介。

•- Age between 18-40.
•- Severe seasonal birch pollen induced allergic rhinitis symptoms for birch verified by skin prick test.
•- Signed informed consent according to IHC/GCP, and national/local regulations.
•- Women of considered childbearing potential (WOCBP) will only be included after a negative highly sensitive pregnancy test according to CTFG recommendations.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 60
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Pregnancy or nursing.
•- Autoimmune or collagen disease.
•- Cardiovascular disease.
•- Hepatic disease.
•- Renal disease.
•- Upper airway disease (non-allergic sinusitis, nasal polyposis, chronic obstructive and restrictive lung disease).
•- Medication with a possible side-effect of interfering with the immune response.
•- Previous immuno- or chemotherapy.
•- Chronic disease.
•- Major metabolic disease.
•- Alcohol or drug abuse.
•- Mental incapability of coping with the study.
•- Known or suspected allergy to the study product.
•- Suspicion of or confirmed bacterial infection.
•- Known allergy to the study drugs, rescue medication”.

发起方